Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Free Cash Flow: 2011-2024

Historic Free Cash Flow for Abeona Therapeutics (ABEO) over the last 14 years, with Dec 2024 value amounting to -$58.5 million.

  • Abeona Therapeutics' Free Cash Flow fell 87.59% to -$23.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 62.87%. This contributed to the annual value of -$58.5 million for FY2024, which is 56.56% down from last year.
  • According to the latest figures from FY2024, Abeona Therapeutics' Free Cash Flow is -$58.5 million, which was down 56.56% from -$37.3 million recorded in FY2023.
  • Abeona Therapeutics' Free Cash Flow's 5-year high stood at -$36.4 million during FY2020, with a 5-year trough of -$69.8 million in FY2021.
  • Moreover, its 3-year median value for Free Cash Flow was -$43.6 million (2022), whereas its average is -$46.5 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Free Cash Flow surged by 47.41% in 2020, and later plummeted by 92.04% in 2021.
  • Over the past 5 years, Abeona Therapeutics' Free Cash Flow (Yearly) stood at -$36.4 million in 2020, then crashed by 92.04% to -$69.8 million in 2021, then spiked by 37.53% to -$43.6 million in 2022, then rose by 14.38% to -$37.3 million in 2023, then slumped by 56.56% to -$58.5 million in 2024.